The Animal Rule and Emerging Infections: The Role of Clinical Pharmacology in Determining an Effective Dose

2009 ◽  
Vol 86 (3) ◽  
pp. 328-331 ◽  
Author(s):  
K L Bergman
Keyword(s):  
Clinical Pharmacology ◽  
Effective Dose ◽  
Emerging Infections ◽  
Animal Rule

Overview of recently approved 505(b)(2) new drug applications (2010-2012): Role of clinical pharmacology

2014 ◽  
Vol 54 (12) ◽  
pp. 1330-1336 ◽  
Author(s):  
Sheetal Agarwal ◽  
Wei Qiu ◽  
Chandrahas Sahajwalla
Keyword(s):  
Clinical Pharmacology ◽  
New Drug

scholarly journals Emerging infectious disease preparedness and response in healthcare: perspectives from COVID-19 and the role of College-Learnt Microbiology

2021 ◽  
Vol 22 (3) ◽  
pp. 312-321
Author(s):  
J. Tonui ◽  
W. Chepkutto ◽  
J. Rotich
Keyword(s):  
Health Care ◽  
Infectious Diseases ◽  
Health Care Providers ◽  
Healthcare Providers ◽  
Emerging Infectious Diseases ◽  
Microbial Pathogens ◽  
Infection Prevention And Control ◽  
Care Providers ◽  
Emerging Infections

Coronavirus disease 2019 (COVID-19) pandemic began in December 2019 in Wuhan City China where it is believed to have been transmitted to humans from an unknown animal species. The public health, social and economic impact of the pandemic world over is detrimental. Health care providers at the frontline in the fight against COVID-19 are at the greatest risk of infection and so far, many have been infected and some have already died from the disease. Thus, it is imperative that healthcare providers have adequate knowledge of infectious diseases and microbial pathogens to comprehend the scale of risk for better recognition and response. Microbiological concepts of infection prevention and control, hand hygiene and aseptic techniques are essential in slowing down the spread of the virus. COVID-19 has proven that infectious agents can emerge from any region in the world and can spread rapidly with ominous consequences to all humanity. This narrative review discusses the role of college-learnt microbiology in health care provider preparedness for emerging infectious diseases in light of the current pandemic. Keywords: Emerging; Infections; Preparedness; Response; Microbiology; COVID-19; Training

scholarly journals The role of clinical pharmacology in enhanced recovery after surgery protocols: a comprehensive review

2020 ◽  
Vol 52 (2) ◽  
pp. 154-164
Author(s):  
Alan Kaye ◽  
Jordan Renschler ◽  
Kelsey Cramer ◽  
Kendall Klein ◽  
Amanda Granier ◽  
...  
Keyword(s):  
Clinical Pharmacology ◽  
Enhanced Recovery ◽  
Enhanced Recovery After Surgery ◽  
Comprehensive Review

Gamma Knife radiosurgery for acromegaly: Evaluating the role of the biological effective dose associated with endocrine remission in a series of 42 consecutive cases

2020 ◽  
Author(s):  
Anne Balossier ◽  
Constantin Tuleasca ◽  
Christine Cortet‐Rudelli ◽  
Gustavo Soto‐Ares ◽  
Marc Levivier ◽  
...  
Keyword(s):  
Effective Dose ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Biological Effective Dose

Role of Guidance and Policy in Enhancing the Impact of Clinical Pharmacology in Drug Development, Regulation, and Use

2020 ◽  
Vol 108 (4) ◽  
pp. 710-715
Author(s):  
Rajanikanth Madabushi ◽  
Elimika Pfuma Fletcher ◽  
Jeffry Florian ◽  
Lauren Milligan ◽  
Anuradha Ramamoorthy ◽  
...  
Keyword(s):  
Clinical Pharmacology ◽  
Drug Development ◽  
The Impact ◽  
Development Regulation

Orphan drug development: the increasing role of clinical pharmacology

2019 ◽  
Vol 46 (5) ◽  
pp. 395-409 ◽  
Author(s):  
Mariam A. Ahmed ◽  
Malek Okour ◽  
Richard Brundage ◽  
Reena V. Kartha
Keyword(s):  
Clinical Pharmacology ◽  
Drug Development ◽  
Orphan Drug ◽  
Orphan Drug Development

Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology

2019 ◽  
Vol 59 (3) ◽  
pp. 287-296 ◽  
Author(s):  
Etienne Chatelut ◽  
Félicien Le Louedec ◽  
Gérard Milano
Keyword(s):  
Clinical Pharmacology ◽  
Checkpoint Inhibitors

scholarly journals CD47 as a Potential Target to Therapy for Infectious Diseases

Antibodies ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 44
Author(s):  
Lamin B. Cham ◽  
Tom Adomati ◽  
Fanghui Li ◽  
Murtaza Ali ◽  
Karl S. Lang
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Infectious Diseases ◽  
Cancer Cells ◽  
Therapeutic Potential ◽  
Antiviral Effect ◽  
Surface Expression ◽  
Inhibitory Effect ◽  
Emerging Infections

The integrin associated protein (CD47) is a widely and moderately expressed glycoprotein in all healthy cells. Cancer cells are known to induce increased CD47 expression. Similar to cancer cells, all immune cells can upregulate their CD47 surface expression during infection. The CD47-SIRPa interaction induces an inhibitory effect on macrophages and dendritic cells (dendritic cells) while CD47-thrombospondin-signaling inhibits T cells. Therefore, the disruption of the CD47 interaction can mediate several biologic functions. Upon the blockade and knockout of CD47 reveals an immunosuppressive effect of CD47 during LCMV, influenza virus, HIV-1, mycobacterium tuberculosis, plasmodium and other bacterial pneumonia infections. In our recent study we shows that the blockade of CD47 using the anti-CD47 antibody increases the activation and effector function of macrophages, dendritic cells and T cells during viral infection. By enhancing both innate and adaptive immunity, CD47 blocking antibody promotes antiviral effect. Due to its broad mode of action, the immune-stimulatory effect derived from this antibody could be applicable in nonresolving and (re)emerging infections. The anti-CD47 antibody is currently under clinical trial for the treatment of cancer and could also have amenable therapeutic potential against infectious diseases. This review highlights the immunotherapeutic targeted role of CD47 in the infectious disease realm.

Sign in / Sign up

Export Citation Format

Share Document